Latest Diagnostics News

4DMedical has submitted its CT:VQ™ software to the FDA, aiming to revolutionize lung ventilation and perfusion imaging by replacing traditional nuclear scans with a non-contrast CT-based solution.

Rhythm Biosciences has successfully validated its second-generation ColoSTAT® Beta assay, confirming its readiness for commercial application in colorectal cancer detection. The Beta kit offers improved precision and faster turnaround times compared to its predecessor.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Omega Oil and Gas has confirmed an extensive oil and gas system in Queensland’s Taroom Trough through high-quality logging at its Canyon-2 well, with DFIT testing now underway to further evaluate reservoir potential.

Microba Life Sciences reveals breakthrough data showing its MetaPanel™ test detects elusive gastrointestinal pathogens in 20% of chronic cases, enabling targeted treatment and complete symptom resolution.

EMVision Medical Devices has enhanced its AI-powered stroke diagnostic algorithm, achieving a notable 95% sensitivity and 80% specificity in recent tests. This progress sets the stage for upcoming pivotal trials and regulatory milestones.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Visionflex Group has landed a significant contract with BHP to deploy its telehealth technology across 13 remote medical centres and a HEMS aircraft in Western Australia, aiming to revolutionize healthcare delivery for mining workers.

IMEXHS Limited reported robust FY24 growth and launched its AI-enabled medical imaging platform Aquila+, setting the stage for expected profitability and accelerated revenue in 2025.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.